# Phio Pharmaceuticals Corp.: Form 10-Q for the period ended Jun 30, 2019

- Company: [Phio Pharmaceuticals Corp.](/companies/phio.md) (CIK 1533040)
- Form: 10-Q
- Filed: 2019-08-12
- Accepted by EDGAR: Aug 12, 2019, 17:01 ET
- Period: 2019-06-30
- Accession: 0001683168-19-002547
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1533040/000168316819002547/phio_10q-063019.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1533040/000168316819002547/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-04-01 to 2019-06-30 | $0 | us-gaap:Revenues |
| Revenue | 6 months, 2019-01-01 to 2019-06-30 | $21.0k | us-gaap:Revenues |
| Research and development | 3 months, 2019-04-01 to 2019-06-30 | $1.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2019-01-01 to 2019-06-30 | $2.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2019-04-01 to 2019-06-30 | −$2.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2019-01-01 to 2019-06-30 | −$4.2m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2019-04-01 to 2019-06-30 | −$2.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2019-01-01 to 2019-06-30 | −$4.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-04-01 to 2019-06-30 | −$0.08 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2019-01-01 to 2019-06-30 | −$0.19 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months, 2019-01-01 to 2019-06-30 | −$4.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2019-01-01 to 2019-06-30 | $16.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2019-06-30 | $10.8m | us-gaap:Cash |
| Current assets | at 2019-06-30 | $11.4m | us-gaap:AssetsCurrent |
| Total assets | at 2019-06-30 | $12.1m | us-gaap:Assets |
| Current liabilities | at 2019-06-30 | $1.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-06-30 | $2.4m | us-gaap:Liabilities |
| Shareholders' equity | at 2019-06-30 | $9.7m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 22,137 characters.

*In this document, “we,” “our,” “ours,” “us,” “Phio” and the “Company” refers to Phio Pharmaceuticals Corp. and our subsidiary, MirImmune, LLC and the ongoing business operations of Phio Pharmaceuticals Corp. and MirImmune, LLC, whether conducted through Phio Pharmaceuticals Corp. or MirImmune, LLC.*

*This management’s discussion and analysis of financial condition as of June 30, 2019 and results of operations for the three and six months ended June 30, 2019 and 2018 should be read in conjunction with the financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the Securities and Exchange Commission (the “SEC”) on March 27, 2019.*

*This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “intends,” “believes,” “anticipates,” “indicates,” “plans,” “expects,” “suggests,” “may,” “should,” “potential,” “designed to,” “will” and similar references, although not all forward-looking statements contain these words. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including those identified in our Annual Report on Form 10-K for the year ended December 31, 2018 under the heading “Risk Factors” and in other filings the Company periodically makes with the SEC. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements contained in this Quarterly Report on Form 10-Q speak as of the date hereof and the Company does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this report.*

### Overview

Phio Pharmaceuticals Corp. is a biotechnology company developing the next generation of immuno-oncology therapeutics based on our self-delivering RNAi (“**sd-rxRNA®”**) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through our proprietary sd-rxRNA platform with utility in immune cells and/or the tumor micro-environment. Our goal is to maximize the power of our sd-rxRNA therapeutic compounds by weaponizing immune effector cells to overcome tumor immune escape providing patients a powerful new treatment option that goes beyond current treatment modalities.

Our development efforts are based on our broadly patented sd-rxRNA technology platform. Our sd-rxRNA compounds do not require a delivery vehicle to penetrate into tissues and cells and are designed to “silence” or down-regulate, the expression of a specific gene which is over-expressed in cancer. We believe that our sd-rxRNA platform uniquely positions the Company in the field of immuno-oncology because of this and the following reasons:

- Efficient uptake of sd-rxRNA to immune cells obviating the need for facilitated delivery (mechanical or formulation);
- Can target multiple genes (i.e. multiple immunosuppression pathways) in a single therapeutic entity;
- Gene silencing by sd-rxRNA has been shown to have a sustained, or long-term, effect *in vivo;*
- Favorable clinical safety profile of sd-rxRNA with local administration; and
- Can be readily manufactured under current good manufacturing practices.

The self-delivering nature of our compounds makes sd-rxRNA ideally suited for use with adoptive cell transfer (“**ACT”**) treatments and direct therapeutic use. ACT consists of the infusion of immune cells with antitumor properties. These cells can be derived from unmodified (i.e. naturally occurring) immune cells, immune cells isolated from resected tumors, or genetically engineered immune cells recognizing tumor neoantigens/neoepitopes cells.

Currently, ACT therapies for the treatment of solid tumors face several hurdles. Multiple inhibitory mechanisms restrain immune cells used in ACT from effectively eradicating tumors, including immune checkpoints, reduced cell fitness and cell persistence. Furthermore, the immunosuppressive tumor micro-environment (the “**TME”**) can pose a formidable barrier to immune cell infiltration and function.

Phio has developed a platform based on our sd-rxRNA technology that allows easy, precise, rapid, and selective non-genetically modified programming of ACT cells (*ex-vivo*, during manufacturing) and of the TME (*in vivo*, by local application), resulting in improved cell-based immunotherapy.

#### Adoptive Cell Transfer

In ACT, immune cells are isolated from patients, donors or retrieved from allogeneic immune cell banks. The immune cells are then expanded and modified before being returned and used to treat the same patient. We believe our sd-rxRNA compounds are ideally suited to be used in combination with ACT, in order to make these immune cells more effective.

ACT includes a number of different types of immunotherapy treatments. These treatments use immune cells, that are grown in a lab to large numbers, followed by administering them to the body to fight the cancer cells. Sometimes, immune cells that naturally recognize a tumor are used, while other times immune cells are modified or “engineered” to make them recognize and kill the cancer cells. There are several types of ACT, including: a.) non-engineered cell therapy in which immune cells are grown from the patient’s tumor or blood, such as tumor infiltrating lymphocytes (“**TILs”**), or from donor blood or tissue such as natural killer (“**NK”**) cells, dendritic cells (“**DC”**) and macrophages, and b.) engineered immune cells that are genetically modified to recognize specific tumor proteins and to remain in an activated state (such as TCRs, CAR T-cells, or CAR-NK cells).

Our approach to immunotherapy builds on well-established methodologies of ACT and involves the treatment of immune cells with our sd-rxRNA compounds during the expansion and modification phase. Because our sd-rxRNA compounds do not require a delivery vehicle to penetrate into the cells, we are able to enhance these cells (for example, by inhibiting the expression of immune checkpoint genes) by merely adding our sd-rxRNA compounds during the expansion process and without the need for genetic engineering. After enhancing these cells *ex vivo*, they are returned to the patient for treatment.

We have a number of collaborations with leading academic centers and corporate institutions. Corporate collaborators include, but are not limited to, Medigene AG, Iovance Biotherapeutics, Inc. and Glycostem Therapeutics BV. Data developed in-house and with our collaborators has shown that PH-762, our lead pipeline compound, can elicit PD-1 checkpoint blockade by silencing PD-1 receptor expression resulting in enhanced T cell activation and tumor cytotoxicity. We have also shown that PH-804, our second pipeline compound, can silence the expression of TIGIT in NK cells and T cells, overcoming their exhaustion and thereby becoming “weaponized.”

We expect to enter the clinic with PH-762 in ACT therapy for solid tumors, such as in melanoma, in the first half of 2020. The Company also expects to enter the clinic with PH-804 in ACT in the second half of 2020.

#### Tumor Micro-Environment

We are exploring the use of our sd-rxRNA directly towards TME targets. Impacting the tumor cells and/or the TME through a direct use of sd-rxRNA, locally administered directly into the tumor, could potentially become an important form of (neo)adjuvant therapy. We believe that this will also show that our contributions with our sd-rxRNA compounds in immuno-oncology are not limited to use with a cell therapy platform. Additionally, the Company has shown in a clinical setting that its sd-rxRNA compounds are safe and well-tolerated following local administration.

Our collaborative research agreement with Gustave Roussy, a leading comprehensive cancer center in France, concentrates on determining the feasibility of our sd-rxRNA platform to target the TME via intra-tumoral injection. Our recent *in-vivo* study with Gustave Roussy demonstrated that sd-rxRNA compound delivered via intra-tumoral injection showed silencing of gene expression with our sd-rxRNA compounds with an 80—85% reduction of the target gene expression in a mouse model of melanoma.

The Company expects to enter the clinic with PH-762 for intratumoral injection in the second half of 2020.

### Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations is based upon our financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates and base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions and could have a material impact on our reported results. Other than our accounting policy for leases in connection with the adoption of Topic 842 on January 1, 2019, as described below, there have been no significant changes to our critical accounting policies since the beginning of this fiscal year. Our critical accounting policies are described in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our Annual Report on Form 10-K for the year ended December 31, 2018, which we filed with the SEC on March 27, 2019.

#### Leases

The Company follows the provisions of the FASB ASC 842. At the inception of a contract, the Company determines whether the contract is or contains a lease based on all relevant facts and circumstances. For contracts that contain a lease, the Company identifies the lease and non-lease components, determines the consideration in the contract and recognizes the classification of the lease as operating or financing. At the commencement date of the lease, the Company recognizes a liability to make lease payments and an asset representing the right to use the underlying asset during the lease term. The Company has elected not to recognize leases with a term less than one year on the balance sheet.

Lease liabilities and the corresponding right of use assets are recorded based on the present value of lease payments to be made over the lease term. The discount rate used to calculate the present value is the rate implicit in the lease, or if not readily determinable, the Company’s incremental borrowing rate. The Company’s incremental borrowing rate is the rate of interest that we would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right of use asset may be required for items such as initial direct costs or incentives received. Lease payments on operating leases are recognized on a straight-line basis over the expected term of the lease. Lease payments on financing leases are recognized using the effective interest method.

### Results of Operations

The following data summarizes the results of our operations for the periods indicated, in thousands:

| Description | Three Months Ended June 30, 2019 | 2018 | Dollar Change | Six Months Ended June 30, 2019 | 2018 | Dollar Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | $– | $58 | $(58) | $21 | $81 | $(60) |
| Operating expenses | (2,059) | (1,957) | (102) | (4,226) | (4,219) | (7) |
| Operating loss | (2,059) | (1,899) | (160) | (4,205) | (4,138) | (67) |
| Net loss | (2,035) | (1,901) | (134) | (4,154) | (4,140) | (14) |

15

### Comparison of the Three and Six Months Ended June 30, 2019 and 2018

### Revenues

The following table summarizes our total revenues, for the periods indicated, in thousands:

| Description | Three Months Ended June 30, 2019 | 2018 | Dollar Change | Six Months Ended June 30, 2019 | 2018 | Dollar Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | $– | $58 | $(58) | $21 | $81 | $(60) |

Revenues for the six months ended June 30, 2019 and three and six months ended June 30, 2018 related to the work performed by the Company as a sub-awardee under the government grant issued to our collaborator BioAxone Biosciences, Inc. from the National Institute of Neurological Disorders and Stroke. Work performed by the Company as a sub-awardee under the grant has been completed. The grant provided funding for the development of a novel sd-rxRNA compound, BA-434, that targets PTEN for the treatment of spinal cord injury.

### Operating Expenses

The following table summarizes our total operating expenses, for the periods indicated, in thousands:

| Description | Three Months Ended June 30, 2019 | 2018 | Dollar Change | Six Months Ended June 30, 2019 | 2018 | Dollar Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $1,146 | $1,183 | $(37) | $2,235 | $2,544 | $(309) |
| General and administrative | 913 | 774 | 139 | 1,991 | 1,675 | 316 |
| Total operating expenses | $2,059 | $1,957 | $102 | $4,226 | $4,219 | $7 |

### Research and Development Expenses

Research and development expenses relate to compensation and benefits for research and development personnel, facility-related expenses, supplies, external services, costs to acquire technology licenses, expenses associated with preclinical and clinical development activities and other operating costs.

Research and development expenses for the three months ended June 30, 2019 decreased 3% as compared with the three months ended June 30, 2018, primarily due to a reduction in licensing fees.

Research and development expenses for the six months ended June 30, 2019 decreased 12% as compared with the six months ended June 30, 2018, primarily due to a reduction in headcount and payroll-related expenses, decreased clinical trial-related fees with the completion of the Company’s dermatology and ophthalmology clinical trials, as well as the completion of the Company’s drug manufacture of PH-762 in the prior year period.

### General and Administrative Expenses

General and administrative expenses relate to compensation and benefits for general and administrative personnel, facility-related expenses, professional fees for legal, audit, tax and consulting services, as well as other general corporate expenses.

General and administrative expenses for the three months ended June 30, 2019 increased 18% as compared with the three months ended June 30, 2018, primarily due to an increase in legal fees.

General and administrative expenses for the six months ended June 30, 2019 increased 19% as compared with the six months ended June 30, 2018, primarily due to an increase in legal fees and an increase in stock-based compensation expense related to the restricted stock issued to the Company’s former Chief Executive Officer in lieu of cash compensation.

### Liquidity and Capital Resources

On August 8, 2017, the Company entered into a purchase agreement (the “**Purchase Agreement”**) and a registration rights agreement with Lincoln Park Capital Fund, LLC (“**LPC”**), pursuant to which the Company has the right to sell to LPC up to $15,000,000 in shares of the Company’s common stock, subject to certain limitations and conditions set forth therein, over the 30-month term of the Purchase Agreement. To date, the Company has sold a total of 495,000 shares of common stock to LPC under the Purchase Agreement for net proceeds of $1,602,000. The Company has approximately $13,300,000 remaining under the Purchase Agreement with LPC.

On April 11, 2018, the Company closed a registered direct offering of 1,510,604 shares of the Company’s common stock at a purchase price of $3.15 per share and in a concurrent private placement, sold warrants to purchase a total of 1,132,953 shares of common stock at a purchase price of $0.125 per underlying warrant share and with an exercise price of $3.15 per share (the “**April 2018 Offering”**). Net proceeds to the Company from the April 2018 Offering were $4,210,000 after deducting placement agent fees and offering expenses paid by the Company.

On October 3, 2018, the Company closed an underwritten public offering of 3,725,714 shares of the Company’s common stock and pre-funded warrants (the “**Pre-Funded Warrants”**) to purchase an aggregate of 17,702,858 shares of common stock (the “**October 2018 Offering”**). The Pre-Funded Warrants are immediately exercisable at a price per share of $0.01 and do not expire. Each share of common stock or Pre-Funded Warrant, as applicable, was sold as a unit with a warrant to purchase one share of common stock at an exercise price of $0.70 per share. The combined public offering price was $0.70 per common stock unit or $0.69 per Pre-Funded Warrant unit. Net proceeds from the October 2018 Offering were $13,193,000 after deducting underwriting discounts and commissions and offering expenses paid by the Company.

On August 7, 2019, the Company entered into a purchase agreement (the “**2019 Purchase Agreement”**) with LPC, pursuant to which the Company has the right to sell to LPC up to 10,000,000 in shares of the Company’s common stock, subject to certain limitations and conditions set forth therein, over the 30-month term of the 2019 Purchase Agreement.

We had cash of $10,816,000 as of June 30, 2019, compared to $14,879,000 as of December 31, 2018. We have reported recurring losses from operations since inception and expect that we will continue to have negative cash flows from our operations for the foreseeable future. Historically, the Company’s primary source of funding has been the sale of its securities. In the future, we will be dependent on obtaining funding from third parties, such as proceeds from the issuance of debt, sale of equity, or strategic opportunities, in order to maintain our operations. There is no guarantee that debt, additional equity or other funding will be available to us on acceptable terms, or at all. If we fail to obtain additional funding when needed, we would be forced to scale back or terminate our operations or to seek to merge with or to be acquired by another company. We believe that our existing cash should be sufficient to fund our operations for at least the next 12 months.

The following table summarizes our cash flows for the periods indicated, in thousands:

|  | Six Months Ended June 30, 2019 | 2018 |
| --- | ---: | ---: |
| Net cash used in operating activities | $(4,108) | $(3,767) |
| Net cash used in investing activities | (16) | – |
| Net cash provided by financing activities | 61 | 5,501 |
| Net (decrease) increase in cash and restricted cash | $(4,063) | $1,734 |

17

### Net Cash Flow from Operating Activities

Net cash used in operating activities was $4,108,000 for the six months ended June 30, 2019, as compared to $3,767,000 for the six months ended June 30, 2018. The increase in cash used in operating activities of $341,000 was primarily attributable to an increase in total changes in operating assets and liabilities primarily due to payments made by the Company for its acquisition of MirImmune Inc. in the prior year period as compared with the payment of its PH-782 drug manufacture during 2019.

### Net Cash Flow from Investing Activities

Net cash used in investing activities for the six months ended June 30, 2019 was $16,000. There were no net cash flows related to investing activities for the six months ended June 30, 2018. The increase in net cash flow used in investing activities was primarily related to the purchase of office and lab equipment.

### Net Cash Flow from Financing Activities

Net cash provided by financing activities was $61,000 for the six months ended June 30, 2019, as compared to $5,501,000 for the six months ended June 30, 2018. The decrease in cash provided by financing activities was due to proceeds received by the Company from the exercise of Pre-Funded Warrants as compared to the proceeds received by the Company from the April 2018 Offering and the issuance of common stock to LPC under the Purchase Agreement during the same prior year period.

### Off-Balance Sheet Arrangements

In connection with certain license agreements, we are required to indemnify the licensor for certain damages arising in connection with the intellectual property rights licensed under the agreement. In addition, we are a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate us to indemnify the other parties to such agreements upon the occurrence of certain events. These indemnification obligations are considered off-balance sheet arrangements in accordance with Accounting Standards Codification Topic 460, “*Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others.”* To date, we have not encountered material costs as a result of such obligations and have not accrued any liabilities related to such obligations in our financial statements. See Note 5 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the SEC on March 27, 2019, for further discussion of these indemnification agreements.

## Controls and procedures

As filed, 1,553 characters.

### Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “**Exchange Act”**), as of the end of the period covered by this report to ensure that information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms.

Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives. We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Based on the evaluation of our disclosure controls and procedures as of the end of the period covered by this report, management concluded that our disclosure controls and procedures were effective as of such date.

### Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the six months ended June 30, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 2,359 characters.

Please carefully consider the information set forth in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on March 27, 2019. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including these risks.

***We may not be able to regain compliance with the continued listing requirements of The Nasdaq Capital Market.***

On November 2, 2018, we received written notice (the “**Notification Letter”**) from the Nasdaq Stock Market (“**Nasdaq”**) notifying us that we are not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of our common stock for the 30 consecutive business days prior to the date of the Notification Letter, we no longer meet the minimum bid price requirement.

The Notification Letter provided an initial 180-day period to regain compliance, which was extended for a second 180-day period on May 14, 2019. As a result of the extension, we have until November 11, 2019 to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. In the event that we do not regain compliance by that date, Nasdaq may commence delisting proceedings and our common stock will trade, if at all, on the over-the counter market, such as the OTC Bulletin Board or OTCQX market, which could adversely impact us by, among other things, reducing the liquidity and market price of our common stock; reducing the number of investors willing to hold or acquire our common stock; limiting our ability to issue additional securities in the future; and limiting our ability to fund our operations.

Filed Aug 12, 2019.
Source: SEC EDGAR, the filing index for accession 0001683168-19-002547. Last ingested by Listed: Nov 12, 2026, 20:44 ET. No prices; not investment advice.
